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Lipoprotein Cholesterol Level: Is Lower Better?We read with interest the letter by Drs. Mascitelli and
Goldstein commenting on our recent paper (1), in
which we showed that the linear relationship be-
tween levels of low-density lipoprotein cholesterol
and cardiovascular events extends to levels <50 mg/
dl. Our ﬁndings are strongly consistent with the
concept “the lower the better,” but translation of
these ﬁndings into clinical practice is still chal-
lenging. Important reasons for this are the lack of
trial evidence for a lipid target-guided strategy and
the lack of evidence-based effective lipid-lowering
therapies beyond statins. The issues raised by Drs.
Mascitelli and Goldstein are less relevant.
Drs. Mascitelli and Goldstein noted that the pri-
mary prevention J-LIT (Japan Lipid Intervention
Trial) showed an increase in risk of mortality among
patients achieving a total cholesterol (TC) level <160
mg/dl. An important limitation of J-LIT is that it was
not a placebo-controlled trial. If J-LIT had a control
group not on statin therapy, it may well have shown
a similar trend. Of the 28 patients in J-LIT who
achieved a TC level <160 mg/dl and died, 12 died of
malignancy. This association is caused by confound-
ing, that is, (subclinical) malignancies decreasing
cholesterol levels (2,3). Large-scale evidence from
statin trials shows that lowering of cholesterol levels
does not increase the risk of malignancies (4). In
addition, in J-LIT, the statistically signiﬁcant increase
in risk of cardiac events among those achieving a TC
level <160 mg/dl was on the basis of just 4 events,
and the nonsigniﬁcant increased risk of stroke was
also on the basis of just 4 events. In our meta-
analysis, 351 fatal cardiovascular events occurredamong those achieving a TC level <160 mg/dl, which
makes our results statistically more reliable.
Drs. Mascitelli and Goldstein also pointed out that
revascularization is a subjective outcome measure.
Although the decision to perform elective revascu-
larization may indeed be subjective, associations
with risk factors tend to be in line with “hard” car-
diovascular outcomes. Still, for 7 of the 8 trials,
elective revascularizations were not included in the
pooled outcomes of our meta-analysis; in the TNT
(Treatment to New Targets) trial, elective revascu-
larization for stable angina and unplanned revascu-
larization for unstable angina could not be separated,
and therefore both were included in the pooled
outcomes (5).
Finally, Drs. Mascitelli and Goldstein stressed the
fact that myopathy is not a trivial adverse effect of
statins in clinical practice. We agree with this remark,
as discussed extensively in our paper. Unfortunately,
data on adverse effects and all-cause mortality
were not obtained from the individual trials for the
purpose of this meta-analysis.
In conclusion, the results of our meta-analysis are
largely consistent with the concept “the lower the
better” and warrant new trials to formally test this
hypothesis.S. Matthijs Boekholdt, MD, PhD
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